Intratumoral Immunotherapy—The Future of Treating Merkel Cell Carcinoma?
Open Access
Abstract
Merkel cell carcinoma (MCC) represents a rare but highly aggressive neuroendocrine skin cancer with limited systemic therapy options for patients who fail or are ineligible for immune checkpoint inhibitors (ICIs). Intratumoral (IT) immunotherapy has emerged as a promising strategy, leveraging the accessibility of tumor lesions and their inherent capacity to trigger immune responses, known as abscopal effects. This review synthesizes the current evidence on IT approaches in MCC, including Toll-like receptor agonists, cytokines, and oncolytic viruses, and highlights their distinct mechanisms of action, while emphasizing the critical need for standardized radiographic response assessment of injected and non-injected lesions. Inconsistent documentation of abscopal responses has hindered quantification of IT therapy’s systemic potential, particularly in a disease where one-third of patients present with metastases and distant relapse is common. We outline MCC-specific rationale for routine lesion-level tracking, and recommendations for IT trial designs and objectives. Rigorous assessments of abscopal data will clarify IT’s role as both rescue therapy and an ICI partner, potentially transforming outcomes in this refractory MCC.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002373)
This publication has 35 references indexed in Scilit:
- First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohortCancer Immunology, Immunotherapy, 2026
- The epidemiology of Merkel cell carcinoma in the United StatesJournal of the American Academy of Dermatology, 2025
- A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumorsRadiotherapy and Oncology, 2024
- Current and emerging intralesional immunotherapies in cutaneous oncologyJournal of the American Academy of Dermatology, 2024
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trialNature Medicine, 2021
- Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillanceCancer Medicine, 2019
- Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patientsJAAD Case Reports, 2019
- Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECCancer Immunology, Immunotherapy, 2017
- Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyCancer, 2016
- The controversial abscopal effectCancer Treatment Reviews, 2005